A method of stratifying a subject with neurological or psychiatric disease manifestation, preferably with neuro-inflammatory autoimmune diseases, comprising a) determining i) a level of B cells in a test cerebrospinal fluid sample obtained from a subject; ii) a level of immune cells per μl in said test CSF sample obtained from said subject; iii) a level of natural killer T cells in said test CSF sample obtained from said subject; iv) a level of monocytes in said test CSF sample obtained from said subject, and v) a level of CD56 dim CD16 + natural killer cells in a test peripheral blood sample obtained from said subject, and b) stratifying said subject as suffering from neuro-inflammatory autoimmune diseases, if the following are fulfilled: i) the level of B cells is increased relative to corresponding levels of B cells in control CSF samples obtained from subjects not suffering from neuro-inflammatory autoimmune diseases; ii) the level of immune cells per μl is increased relative to corresponding levels of immune cells per μl in said control CSF samples obtained from said subjects not suffering from neuro-inflammatory autoimmune diseases; iii) the level of NKT cells is decreased relative to corresponding levels of NKT cells in said control CSF samples obtained from said subjects not suffering from neuro-inflammatory autoimmune diseases; iv)the level of monocytes is decreased relative to corresponding levels of monocytes in said control CSF samples obtained from said subjects not suffering from neuro-inflammatory autoimmune diseases; v) the level of CD56 dim CD16 + NK cells is decreased relative to corresponding levels of CD56 dim CD16 + NK cells in control PB samples obtained from said subjects not suffering from neuro-inflammatory autoimmune diseases, wherein the combination of said levels i) - v) of step b) is indicative for whether said subject is suspected to suffer from neuro-inflammatory autoimmune diseases or from another neurological or psychiatric disease manifestation other than neuro-inflammatory autoimmune disease. a) determining i) a level of B cells in a test cerebrospinal fluid sample obtained from a subject; ii) a level of immune cells per μl in said test CSF sample obtained from said subject; iii) a level of natural killer T cells in said test CSF sample obtained from said subject; iv) a level of monocytes in said test CSF sample obtained from said subject, and v) a level of CD56 dim CD16 + natural killer cells in a test peripheral blood sample obtained from said subject, and i) a level of B cells in a test cerebrospinal fluid sample obtained from a subject; ii) a level of immune cells per μl in said test CSF sample obtained from said subject; iii) a level of natural killer T cells in said test CSF sample obtained from said subject; iv) a level of monocytes in said test CSF sample obtained from said subject, and v) a level of CD56 dim CD16 + natural killer cells in a test peripheral blood sample obtained from said subject, and b) stratifying said subject as suffering from neuro-inflammatory autoimmune diseases, if the following are fulfilled: i) the level of B cells is increased relative to corresponding levels of B cells in control CSF samples obtained from subjects not suffering from neuro-inflammatory autoimmune diseases; ii) the level of immune cells per μl is increased relative to corresponding levels of immune cells per μl in said control CSF samples obtained from said subjects not suffering from neuro-inflammatory autoimmune diseases; iii) the level of NKT cells is decreased relative to corresponding levels of NKT cells in said control CSF samples obtained from said subjects not suffering from neuro-inflammatory autoimmune diseases; iv)the level of monocytes is decreased relative to corresponding levels of monocytes in said control CSF samples obtained from said subjects not suffering from neuro-inflammatory autoimmune diseases; v) the level of CD56 dim CD16 + NK cells is decreased relative to corresponding levels of CD56 dim CD16 + NK cells in control PB samples obtained from said subjects not suffering from neuro-inflammatory autoimmune diseases, wherein the combination of said levels i) - v) of step b) is indicative for whether said subject is suspected to suffer from neuro-inflammatory autoimmune diseases or from another neurological or psychiatric disease manifestation other than neuro-inflammatory autoimmune disease. i) the level of B cells is increased relative to corresponding levels of B cells in control CSF samples obtained from subjects not suffering from neuro-inflammatory autoimmune diseases; ii) the level of immune cells per μl is increased relative to corresponding levels of immune cells per μl in said control CSF samples obtained from said subjects not suffering from neuro-inflammatory autoimmune diseases; iii) the level of NKT cells is decreased relative to corresponding levels of NKT cells in said control CSF samples obtained from said subjects not suffering from neuro-inflammatory autoimmune diseases; iv)the level of monocytes is decreased relative to corresponding levels of monocytes in said control CSF samples obtained from said subjects not suffering from neuro-inflammatory autoimmune diseases; v) the level of CD56 dim CD16 + NK cells is decreased relative to corresponding levels of CD56 dim CD16 + NK cells in control PB samples obtained from said subjects not suffering from neuro-inflammatory autoimmune diseases,